NCT06735664View on ClinicalTrials.gov

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

PHASE1RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

December 13, 2027

Study Completion Date

December 13, 2027

Conditions
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo ultrasound guided biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo optional bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

BIOLOGICAL

Odronextamab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

PROCEDURE

Ultrasound Imaging

Undergo ultrasound guided biopsy

DRUG

Zanubrutinib

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER